

UPDATE ON BROOKFIELD PROPOSAL – EXCLUSIVITY PERIOD

19 NOVEMBER 2018

Healthscope Limited (“Healthscope”) today announced that it has provided due diligence materials to Brookfield Capital Partners Ltd as required under the Process Deed announced on 12 November 2018.

Accordingly, the exclusivity period under that deed will end on Friday, 21 December 2018.

The Healthscope Board will keep the market informed of any material developments in accordance with its continuous disclosure requirements.

Healthscope shareholders are reminded that:

- there is no certainty that the Brookfield proposal will result in a takeover bid or scheme of arrangement being proposed; and
- a takeover bid or scheme of arrangement will only proceed if the conditions to the proposal (as described in the 12 November 2018 announcement, which includes a condition that Brookfield is satisfied with its due diligence enquiries) are met and a binding agreement is then entered into between Healthscope and Brookfield.

Further enquiries:

David Shirer
General Manager Investor Relations
Phone: +61 3 9926 7766 / +61 407 512 521

Natalie Rachele
Manager Investor Relations
Phone: +61 3 9926 7522 / +61 413 685 164

About Healthscope

Healthscope (ticker: HSO) is a leading private healthcare provider with 43 private hospitals in Australia and pathology operations across New Zealand.

Healthscope has a team of over 16,650 people and 17,500 Accredited Medical Practitioners, providing care to patients ranging from pathology tests to complex surgery.

We place the highest priority on quality clinical outcomes, transparency of reporting and elevating the overall patient experience. Healthscope was the first private hospital operator in Australia to report performance against quality and clinical outcome metrics publicly, just one part of our program to maintain and continually improve our high standards.